BioNTech: Stable COVID-19 Vaccine Base and Catalyst-Rich Oncology Pipeline Support Buy Rating

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on BioNTech SE, with a price target of $143.00.

Evan Seigerman has given his Buy rating due to a combination of factors related to both BioNTech’s current business and its future pipeline. He views the COVID-19 vaccine franchise as likely to decline only gradually and remain a meaningful, relatively stable revenue source in the near to medium term, which should underpin the valuation rather than weigh on it. At the same time, he highlights 2026 as a year rich in clinical catalysts, led by pivotal readouts for pumitamig in first-line non-small cell lung cancer and additional trials in triple-negative breast cancer and colorectal cancer, where early data and mechanistic rationale suggest potential differentiation versus competing agents. He also points to upcoming results from other oncology assets, such as gotistobart in later-line squamous NSCLC, where early Phase 3 survival data appear encouraging, though fuller safety data are still pending.

Evan further underscores that BioNTech’s broader oncology portfolio—including programs like BNT113 in HPV-positive head and neck cancer and T-Pam in HER2-driven endometrial and breast cancers—offers multiple, less appreciated opportunities for incremental upside. In his view, these diversified pipeline shots on goal can more than offset the expected taper in COVID revenues and help reshape the investment narrative around oncology growth. He also notes that BioNTech’s sizable cash position and balance sheet strength provide substantial flexibility for business development, partnerships, and external innovation, which can supplement internal R&D progress. Taken together, the combination of a still-supportive COVID vaccine base, a catalyst-heavy oncology pipeline with potential competitive advantages, and meaningful capital for strategic expansion underpins his positive stance and supports a Buy (Outperform) recommendation on BNTX shares.

In another report released on January 5, Citi also maintained a Buy rating on the stock with a $145.00 price target.

Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BNTX in relation to earlier this year.